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Abstract 
 
While numerous mouse models of B cell malignancy have been developed via the enforced 
expression of defined oncogenic lesions, the feasibility of generating lineage-defined human B 
cell malignancies using mice reconstituted with modified human hematopoietic stem cells 
remains unclear.  In fact, whether human cells can be transformed as readily as murine cells 
by simple oncogene combinations is a subject of considerable debate. Here, we describe the 
development of humanized mouse model of MYC/BCL2-driven “double-hit” lymphoma. By 
engrafting human hematopoietic stem cells transduced with the oncogene combination into 
immunodeficient mice, we generate a fatal B malignancy with complete penetrance. This 
humanized-MYC/BCL2-model (hMB) accurately recapitulates the histopathological and 
clinical aspects of steroid-, chemotherapy- and rituximab-resistant human “double-hit” 
lymphomas that involve the MYC and BCL2 loci. Notably, this model can serve as a platform 
for the evaluation of antibody-based therapeutics. As a proof of principle, we used this model 
to show that the anti-CD52 antibody alemtuzumab effectively eliminates lymphoma cells from 
the spleen, liver, and peripheral blood, but not from the brain. The hMB humanized mouse 
model underscores the synergy of MYC and BCL2 in “double-hit” lymphomas in human 
patients. Additionally, our findings highlight the utility of humanized mouse models in 
interrogating therapeutic approaches, particularly human-specific monoclonal antibodies.  
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Introduction 
The accumulation of sequential or simultaneous genetic alterations is a key feature of the 
development of human malignancies. Deregulated c-MYC and BCL2 together have recently 
been found to promote the development of so-called “double-hit” high-grade human B-cell 
lymphomas/leukemias (1-4).  Other genes involved in translocations, like BCL6 and CCND1, 
have also been described, however c-MYC and BCL2 represent the most frequent 
combination. These “double-hit” lymphomas include patients with various histomorphological 
classifications such as follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell 
lymphoma, mature B-cell neoplasia not otherwise specified, Burkitt’s Lymphoma and acute 
lymphoblastic lymphoma/leukemia (1). “Double-hit” lymphomas represent an estimated 2% of 
all B-cell malignancies, but they are also the most refractory to therapy (with an average 
survival of 18.6 months) and represent a major clinical challenge (5-7).  Notably, the 
combination of deregulated c-MYC and BCL2 have been shown by numerous groups to 
promote a rapid and aggressive pro-B cell malignancy in mice (8-10).  These tumors have 
been used as an effective pre-clinical model, but are not amenable to the analysis of human-
specific therapies.   
 
Antibody-based therapies targeting CD20 using rituximab have significantly improved the 
general patient outcome in B-cell lymphoma patients, however “double-hit” lymphomas do not 
express or express much reduced levels of CD20 (11, 12).  The development of more 
personalized and effective therapies including antibody based approaches for treating 
patients harboring “double-hit” lymphomas has been hampered by the lack of diagnostic 
awareness, therapeutic options and suitable pre-clinical models for therapeutic development. 
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While conventional transgenic models can be quite effective at assessing the response of 
tumors to general cytotoxic agents, they cannot be used to evaluate the efficacy of human-
specific therapeutic antibodies.  This includes murine models in which the human antigen has 
been introduced (13). A more recent approach to modeling hematologic malignancies is to 
engraft immunodeficient mice with genetically modified human hematopoietic stem cells 
(HSCs) (14).  Here, we used this approach to determine whether we could generate a B cell 
malignancy that phenocopies human “double-hit” lymphomas. We then used this humanized 
mouse model as a preclinical platform for examining the efficacy of cytotoxic and human-
specific antibody based therapies. 
 
Results and Discussion 
To model “double-hit” lymphoma in humanized mice, we engineered c-MYCT58A and BCL2 
overexpression in human B-lineage cells. Here, c-MYCT58A is an oncogenic allele of Myc 
found in transforming avian alleles of Myc, as well as many cases of human Burkitt’s 
lymphoma (15-17).  Following in vitro expansion, human cord-blood derived CD133+ HSCs 
were transduced with lentiviruses expressing GFP alone, GFP-BCL2, GFP-MYCT58A or GFP-
c-MYC T58A-BCL2 under the control of a B-cell specific Eµ-enhancer/CD19-promoter (18-21). 
Transduced HSCs were then engrafted into sub-lethally irradiated NOD-scid Il2Rg-/- (NSG) 
mice (106 per recipient) (Figure 1A) (22). Four weeks after reconstitution, human CD45+ 
leukocytes were readily detected in the peripheral blood of reconstituted mice, suggesting 
humanization of the hematopoietic system.   
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Nine weeks after reconstitution, 10.8% of human CD45+ cells in the peripheral blood were 
GFP+ in mice that received the GFP virus-transduced HSCs (referred to as GFP mice, 2A).   
No GFP+ cells were observed in GFP-MYCT58A mice, while 33.2% of human CD45+ cells were 
GFP+ in GFP-BCL2 mice – with comparable cell stage distribution throughout B-cell 
developmental (Figure 1B; Supplemental Tables 1 and 2). Additionally, no tumor or clinical 
sign of malignant transformation was ever detected in GFP, GFP-MYCT58A or GFP-BCL2 mice 
during the same observation period. Compared to GFP-only mice GFP-BCL2 developed a 
mild hyperplasia of human B-cells over the course of several months (Figure 1C), however no 
clinical symptoms arose from the increased number of B-cells in these mice. Furthermore, 
transfer of GFP-sorted cells from GFP-BCL2 mice failed to induce tumors in secondary 
recipient mice. 
 
In contrast, nearly all human CD45+ cells were GFP+ in in mice that received the GFP-c-MYC 
T58A-BCL2 virus-transduced HSCs (referred to as hMB mice)(Figure 1B).  With time, hMB mice 
gradually lost weight, developed massive splenomegaly and occasionally ataxia and died on 
average 12 weeks post-HSC transfer (Figure 2A,B). Histological examination revealed the 
presence of uniform blast-like cells with multiple prominent nucleoli and mitotic figures in the 
peripheral blood, bone marrow, and spleen of the hMB mice; tumor cells were also present in 
the liver, kidneys, muscles, mediastinum, retroperitoneum and, notably, the leptomeningeal 
spaces in the brain (Figure 2C-F, Supplemental Figure 1).  Flow cytometry analysis showed 
that the majority of splenocytes (11) from symptomatic hMB mice were positive for GFP as 
well as human CD45, CD10, CD19, IL-7Rα CD22, cytoplasmic CD79a, cytoplasmic IgM, and 
TdT, but low for CD20 and negative for surface IgM (Figure 3A) - an immunophenotype most 
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characteristic of a pre-B cell lymphoma/leukemia and consistent with previous 
immunophenotyping of patient “double-hit” lymphoma cells. Additionally, expression of the 
introduced transgenes MYC and BCL2 could be observed in all lymphoma cells derived from 
hMB mice (Supplemental Figure S2). Southern blot hybridization of tumor DNA with a GFP-
specific probe revealed either monoclonal or oligoclonal lymphomas (Supplementary Figure 
3), suggesting a potential requirement for one or more additional alterations during tumor 
development. 
 
In order to identify secondary genetic lesions involved in the pathogenesis of the leukemia 
model we performed karyotyping of primary cells derived from three hMB mice after disease 
onset. In one mouse, we failed to detect a second cytogenetic alteration. A trisomy 7 bearing 
subclone (formal karyotype: 47, XX, +7 [8] / 46, XX [14]) was detected in a second hMB 
mouse (Figure 3B). In the third mouse, we could identify an elongation of chromosome 17p 
and a subclone bearing an elongation of chromosome 12p (formal karyotype 46, XX, 
add(17)(q25.3)[13] / 46, XX, idem, add(12)(p13.3)[8] / 46, XX[4]) (Figure 3C). However, the 
elongation at chromosome 12p did not involve the ETV locus, as characterized by FISH 
probing.  Thus, the formation of leukemic clones does not require an obligate defined 
secondary major chromosomal loss or translocation. However, we identified trisomy 
chromosome 7 in 1 out of 3 karyotyped lymphomas.  This alteration is commonly found in 
patient-derived “double-hit” lymphomas/leukemias (2). 
 
To verify that the disease arising in hMB mice indeed represented a bona fide malignancy, we 
transplanted 106 hMB lymphoma cells purified from primary hMB mice into unirradiated 
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secondary NSG recipients. GFP+ lymphoma cells were detectable in the peripheral blood of 
the secondary recipients after 14 days, and onset of disease symptoms was evident after 21-
28 days. Onset of disease in transplanted mice is dependent on total numbers of injected 
cells, as transplantation of 2x105 cells gave rise to disease in recipient after 4-6 weeks. 
However, in all cases, the resulting disease was clinically and histologically identical to that in 
primary donor hMB mice. Thus, the coordinated expression of MYC and BCL2 are capable of 
producing a completely penetrant early B cell malignancy. 
 
The generation of large cohorts of secondary mice bearing synchronously appearing hMB 
lymphomas allowed us to examine the effects of a diverse set of therapeutics on a genetically 
defined lymphoma.  Treatment was initialized upon the presentation of leukemic outgrowth or 
development of the above-mentioned clinical symptoms. When used individually, 
dexamethasone showed no effect (Figure 4A). Doxorubicin had a statistically significant, but 
minimal, effect on reducing tumor burden, while cytarabine and total body irradiation only had 
a modest effect (Figure 4A).  A partial response could be observed with cyclophosphamide, 
including some reduction in brain infiltrating malignant cells (Figure 4B). However, survival of 
mice was not significantly improved after cyclophosphamide chemotherapy (Figure 4C). Thus, 
these lymphomas were both steroid and chemotherapy resistant.  Surprisingly an anti-BCL2 
targeted approach towards hMB lymphoma cells, using the BCL2 inhibitor ABT-737, also 
failed to promote lymphoma cell apoptosis (Supplemental Figure S4). Importantly, this 
humanized mouse model of “double-hit” lymphoma allowed us to assess the efficacy of 
human-specific antibody-based therapeutics. We took advantage of the hMB lymphoma cells’ 
expression of CD52 (Figure 3E) and tested the human CD52-specific therapeutic antibody 
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alemtuzumab (Campath-1H, Genzyme). Alemtuzumab treatment significantly prolonged 
overall survival of lymphoma mice (Figure 4C, p<0.01 in all experiments). In contrast, an anti-
CD20 treatment approach using rituximab (MabThera, Roche) failed to induce treatment 
response (Supplemental Figure 5). Rituximab failure in this context is consistent with low 
CD20 expression by these tumors, an immunophenotype consistent with that of patient-
derived “double-hit” lymphomas (11).  
 
Notably, seven days after the start of alemtuzumab treatment, tumor cell burden was reduced 
approximately 100-fold in the peripheral blood, the spleen, and the liver (Figure 4D). However, 
tumor cell burden was not reduced in the brain. Using fluorescently labeled alemtuzumab in 
vivo, we observed antibody bound to GFP+ lymphoma cells in the spleen, while no specific 
staining could be detected in the brain (Figure 4E-G) Thus, alemtuzumab cannot efficiently 
target lymphoma cells in the central nervous system, probably because the antibody 
molecules do not cross the blood-brain barrier, and all alemtuzumab-treated mice eventually 
succumbed to a relapse of the malignant disease. 
 
Here, we have developed a humanized mouse model of “double-hit” lymphoma by directing 
coordinated overexpression of c-MYC and BCL2 in human HSC-derived B lineage cells.  
Notably, development of these lymphomas was dependent upon a combination of both the 
MYC and BCL2 oncogenes, as neither individual oncogene could readily promote malignant 
growth. In mice, introduction of Eµ-myc and Eµ-bcl2 alteration leads to the very rapid 
formation of polyclonal lymphomas (10). However, lymphoma formation is not strictly 
dependent on Bcl2 co-expression (23), as both Eµ-myc and c-MycT58A mice can eventually 
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acquire secondary alterations and develop monoclonal or oligoclonal disease.  In a human 
hematopoetic stem cell based system, we show that a single alteration with B-cell 
overexpression of c-MYCT58A is not sufficient for lymphoma formation within the 6-month 
period of the experiment. In particular, no GFP-MYC B cells were detected in the humanized 
mouse, suggesting that the residual pro-apoptotic features of MYCT58A (24) result in the 
ablation of these cells prior to the occurrence of pro-survival mutations.  It remains unclear 
whether the MYCT58A allele makes any significant contribution to tumor development in this 
context, but the uniformly high levels of BCL2 seen by western blot in tumor samples 
suggests the presence of a high apoptotic threshold limiting tumor lymphoma development.  It 
also remains to be determined how frequently c-MYC is mutated in “double-hit” lymphomas, 
however the common presence of these mutations on translocated Myc alleles suggests that 
“double-hit” lymphomas that are initiated by MYC translocations will show similar MYC 
alterations.   
 
The GFP-BCL2 construct induced an increased persistence of non-transformed B-cells, but 
no B-cell malignancies – a phenotype that mirrors murine phenotypes of Bcl-2-
immunoglobulin transgenic mice (25). While methodological differences exist between these 
“humanized” experiments and similar murine efforts, including both viral and promotor choice, 
these data suggest that perhaps an additional “hit” beyond MYC and BCL2 expression is 
necessary to induce a malignant transformation or clinical phenotype in human cells.  Further 
work, including retroviral insertion site analysis will be required to identify cooperating 
alterations in this context. 
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Human cells are thought to show greater resistance towards malignant transformation than 
murine cells.  For example, in mouse cells, perturbation of only two pathways has been 
shown to be sufficient to induce malignant transformation, while up to six pathways need to be 
altered in corresponding human cells (26). Thus, it was unexpected to see a robust malignant 
phenotype with 100% penetrance in the hMB model. This stands in contrast to other recent 
studies involving the introduction of defined oncogenic perturbations into human 
hematopoietic stem cells, where engraftment of these cells into immunodeficient recipient 
mice has resulted in variable disease penetrance or non-malignant phenotypes (27-31). For 
example, leukemic transformation was reported following introduction of the MLL-fusion 
proteins MLL-AF9 and MML-ENL (14) into HSCs, whereas MLL-AF4 and AML-ETO failed to 
induce malignant transformation (32, 33).  Thus, the oncogenic synergy of MYCT58A and BCL2 
shown in the hMB model underlines their central role as “driving” events in tumor 
pathogenesis.  
 
The use of a humanized model of lymphoma in preclinical modeling of therapeutic regimens 
provides several advantages relative to conventional transgenic or murine transgenic models. 
First, we can generate a de novo arising human malignancy not harboring artifacts from 
extensive tissue culture of cell line-based xenograft approaches. Additionally, these tumors 
can be modified rapidly ex vivo and, unlike many xenograft tumors, are highly amenable to 
transplantation into recipient mice. As a proof of principle we show that antibody-mediated 
targeting of CD52 can produce potent anti-tumor effects in this model.  This monoclonal anti-
CD52 antibody has been in clinical use for relapsed CLL and is currently under investigation 
in several clinical trials for other malignancies (34). Treatment outcome in this humanized 
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model may better predict the effects of antibody-based therapy in patients. Thus far 
alemtuzumab-containing protocols have not been specifically addressed to “double-hit” 
lymphomas, however analogous to recent trials in T-NHL, a CHOP-alemtuzumab approach 
specifically addressed to “double-hit” lymphomas might represent a promising strategy 
despite the severe toxicity profile of the antibody (35). 
 
Currently, a multitude of novel compounds are in preclinical development for treatment 
refractory leukemias/lymphomas. However, given the low frequency of diagnosed “double-hit” 
lymphomas, clinical trials for this malignancy are necessarily limited in size and number. 
Consequently, initial pre-clinical testing involving an accurate humanized mouse model may 
offer the opportunity to evaluate human-specific antibody and chemo-immunotherapeutic 
regimens prior to human clinical trials. 
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Figure Legends 
Figure 1. A humanized mouse model of “double-hit” lymphoma. (A) A schematic diagram 
showing the lentiviral vector in which the human B cell-specific enhancer-promotor controls 
the expression of GFP, c-MYC, and BCL2, transduction of human hematopoietic stem cells 
(HSC), and generatioin of humanized mice.  The dot-plot shows human CD45 (hCD45) 
versus murine CD45 (mCD45) staining of peripheral blood mononuclear cells of a 
representative humanized mouse 9 weeks after reconstitution. (B) Peripheral blood 
mononuclear cells (PBMCs) from NSG mice injected with lentivirally-transduced human 
HSCs. Peripheral blood was analyzed for hCD45, mCD45 and GFP 9 weeks after 
engraftment in GFP, GFP-MYC, GFP-BCL2 and GFP-MYC-BCL2 mice (n=5). Histograms 
show GFP expression gating on human CD45+ cells indicated in Figure 1A. Murine cells are 
GFP-negative.  Percentages of GFP+ cells are indicated. (C) Time dependent development of 
B-cell hyperplasia in GFP-BCL2 mice. Sublethally irradiated adult NSG mice were engrafted 
with human CD133+ cells that had been spin-infected with lentivirus expressing either GFP 
alone or GFP plus BCL2. At the indicated times following engraftment, PBMCs from these 
mice were analyzed for GFP expression.  All cells were gated on human CD45+ cells.  
Numbers indicate percent cells in the indicated region. Representative data from at least 5 
mice are shown 
 
Figure 2: Clinical presentation of the hMB model. (A) Kaplan-Meier survival analysis of GFP-
control (G; n=9), GFP-BCL2 (GB; n=5), GFP-MYC (GM; n=5) and GFP-MYC-BCL2 (hMB; 
n=9). (B) Representative image of a control (GFP) and a leukemic hMB spleen at week 12 
post injection and corresponding representative low-magnification cross-section of a control 
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(GFP) and a leukemic hMB spleen. (C-F) Histomorphological analysis of leukemic mice. (C) 
Bone marrow smear (Giemsa-Wright staining). (D) Bone marrow section (H&E staining) with 
(E) Spleen high magnification showing lymphoma blast cells. (F) Brain section (H&E staining) 
showing leptomeningeal infiltration by leukemic blasts. 
 
 
Figure 3. Flow cytometry analysis of reconstituted mice.  (A) Flow cytometry analysis of 
lymphoma cells from spleens of diseased hMB mice. Splenocytes were stained for hCD45 as 
well as human CD19, CD10, surface IgM (sIgM), CD20, CD52, surface CD22 (sCD22), IL-
7Rα, TdT, cytoplasmic IgM (cyIgM), or cytoplasmic CD79a (cyCD79a). Dot plots show GFP 
versus the indicated surface staining of hCD45+ cells. Histograms show TdT, IL-7Rα, cyIgM 
and cyCD79a staining of hCD45+ cells (dark line) versus isotype controls (faint lines). 
Karyotyping of tumors showing (B) trisomy 7 and (C) an elongation at chromosome 12p. 
Representative metaphases from a minimum of 22 metaphases per sample are displayed. 
 
Figure 4. Therapeutic modeling in the hMB “double-hit” lymphoma model. (A) Secondary 
transplant mice were treated upon presence of leukemic cells in the peripheral blood at day 
21 post transplant (corresponding to day 1 of treatment) with dexamethasone (DEX; 10 
mg/kg), doxorubicin (DOX;5 mg/kg), cytarabine (ARA-C;50 mg/kg), total body irradiation 
(RAD; 5 Gy), cyclophosphamide (CYP; 300 mg/kg ) or alemtuzumab (ALEM; 5 mg/kg). 
Treatment response was assessed at day 7 post treatment by measuring total number of 
GFP+ lymphoma cells in the spleen. (B) Comparison of tumor burden in peripheral blood, 
spleen and brain 8 days after initiating cyclophosphamide treatment. GFP+ lymphoma cells 
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were counted using the C6 flow cytometer (Accuri Cytometers). Each symbol represents one 
mouse; average and standard error are shown for each group. P values of indicated 
comparisons are shown (n.s.=non-significant). (C) Kaplan-Meier survival analysis of 
secondary hMB recipient mice that received intravenous injections of alemtuzumab (Alem., 5 
mg/kg) or of vehicle control; 3 injections over 7 days, delivered on days 1, 4, and 7). (D) 
Comparison of tumor burden in different organs 8 days after initiating alemtuzumab treatment. 
GFP+ lymphoma cells were counted using the C6 flow cytometer (Accuri Cytometers). Each 
symbol represents one mouse; average and standard error are shown for each group. P 
values of indicated comparisons are shown (n.s.=non-significant). (E) Visualization of the in 
vivo distribution of alemtuzumab 24 hours following injection into either non-reconstituted 
NSG mice or NSG mice transferred with hMB lymphoma cells. Mice were injected with 5 
mg/kg AlexaFluor750-labeled alemtuzumab and distribution of fluorescence assessed after 
6h. Representative scans of healthy control vs. lymphoma hMB mice showing enriched signal 
from spleen and long bones. (F) Alemtuzumab binding to target organs comparing non-
transplanted healthy NSG mice to hMB-mice. Brains were dissected from the skull and 
assessed separately for quantification. Spleens were examined in situ. Photon emission from 
defined region of interest was quantified for spleen and brain (n=6 each). (G) Flow cytometry 
analysis of AlexaFLuor750-alemtuzumab binding to GFP+ lymphoma cells in the spleen but 
not in brain parenchyma and submeningeal space. Cells were directly subjected to flow 
cytometry after organ dissociation  
 
 




